Ionis Pharmaceuticals initiated with a Neutral at Redburn Atlantic
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.
BioWorld15d
Ono scoops Ionis' hematology candidate sapablursen for up to $940M
Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...
The Pharma Letter15d
Incyte’s JAK1 blocker meets goals in Phase III trials
US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. The company said the trials, which tested the drug as an option for ...
FiercePharma19d
Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. Japan's Ono Pharmaceutical bought an antisense ...
PipelineReview.com21d
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the ...
Nasdaq21d
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an investigational RNA-based therapy for polycythemia vera (PV). A rare blood cancer ...
Zacks Investment Research on MSN21d
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...
Benzinga.com21d
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Sapablursen, an investigational RNA therapy for polycythemia vera, is in a fully enrolled Phase 2 trial. Pelosi’s latest AI pick skyrocketed 169% in just one month. Click here to discover the ...
FierceBiotech21d
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
The RNA-targeted medicine, called sapablursen, is designed to reduce the production of a protein called TMPRSS6. The idea is that this increases the expression of hepcidin, which is the key ...
Business Wire21d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...